We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+0.87%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.17B
AUM Growth
-$132M
Cap. Flow
+$330M
Cap. Flow %
10.43%
Top 10 Hldgs %
55.39%
Holding
52
New
18
Increased
15
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$125M
2
ZGNX
Zogenix, Inc.
ZGNX
+$110M
3
ASND icon
Ascendis Pharma A/S
ASND
+$94.8M
4
ADVM
Adverum Biotechnologies
ADVM
+$84.8M
5
EXEL icon
Exelixis
EXEL
+$82.8M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$680M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$76.1M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$54M
4
DVAX
Dynavax Technologies
DVAX
+$13.5M
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 93.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THOR
51
DELISTED
Synthorx, Inc. Common Stock
THOR
– –
-9,724,598
Closed -$680M
BOLD
52
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-902,383
Closed -$54M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

RA Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, RA Capital Management held 52 positions worth $3.17B, down 4% from $3.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management deployed $330M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Adverum Biotechnologies: 727,271 shares worth $71.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Galera Therapeutics, Inc. Common Stock, an estimated $2.08M trimmed.

  • RA Capital Management's largest Q1 2020 buy was Adverum Biotechnologies: 727,271 shares worth $71.1M.
  • RA Capital Management added most to Axsome Therapeutics in Q1 2020, an estimated $125M increase.
  • RA Capital Management's biggest Q1 2020 reduction was Galera Therapeutics, Inc. Common Stock, cutting an estimated $2.08M.
  • RA Capital Management fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $680M.
  • RA Capital Management's ten largest holdings make up 55% of its $3.17B portfolio in Q1 2020.
  • RA Capital Management opened 18 new positions and closed 4 in Q1 2020.
  • RA Capital Management's portfolio value fell 4% quarter-over-quarter to $3.17B.

Based on RA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.